The article is well written and covers plenty of valid arguments against the amyloid hypothesis and shines a light on the weaknesses of the new amyloid clearing drugs that have recently been approved to treat Alzheimer's. However it must be said that there aren't many counter arguments presented. There is a very large body of evidence in favour of the amyloid hypothesis that isn't covered here. The article focuses quite heavily on the 2006 research article which falsified results linking aβ*56 to Alzheimer's disease (perhaps understandingly given the author broke the original story) but no mention is made of other amyloids that are also linked to Alzheimer's disease. I also think describing the field as a "mafia" is incorrect as many leading proponents of the amyloid hypothesis admit that other factors also contribute towards Alzheimer's (see Sir Professor John Hardy's comments in: https://www.alzheimers.org.uk/for-researchers/explaining-amyloid-research-study-controversy)

This article is relatively clear and provides evidence and quotes from several sources bemoaning the fact that Donanemab will not be available on the NHS. I would however question the balance of the article, which contains no sources backing the move and provides little background as to why this drug won't be available besides it being "too expensive".